Curare
Consulting firm focused on translational science and early clinical drug development. Services include strategic drug development planning, translational biomarker strategies, clinical pharmacology (dose selection and PK/PD analysis), regulatory interaction support and targeted training in pharmacokinetics. Team experience spans preclinical in vitro/in vivo pharmacology, first-in-human studies, proof-of-concept and pediatric development.
Industries
Nr. of Employees
small (1-50)
Curare
Boxtel, North Brabant, Netherlands
Products
Pharmacokinetics Course Basel, Switzerland
A 2-day basic pharmacokinetics training course tailored to explore fundamental aspects of pharmacokinetics, physiological processes, basic PK principles, and the utilization of PK data in drug development.
Clinical pharmacology consulting services
Expert services translating nonclinical results into targeted early clinical development programs, guiding dose selection, biomarker inclusion, and risk mitigation.
Translational Science Consulting Services
Consulting services applying translational science principles to evaluate discovery aspects in the context of clinical relevance, biomarker strategy, and dose selection.
Strategic drug development
Innovative clinical drug development plans and study designs designed to enable informed and stepwise decision making for unique development programs.
Pharmacokinetics Course Basel, Switzerland
A 2-day basic pharmacokinetics training course tailored to explore fundamental aspects of pharmacokinetics, physiological processes, basic PK principles, and the utilization of PK data in drug development.
Clinical pharmacology consulting services
Expert services translating nonclinical results into targeted early clinical development programs, guiding dose selection, biomarker inclusion, and risk mitigation.
Translational Science Consulting Services
Consulting services applying translational science principles to evaluate discovery aspects in the context of clinical relevance, biomarker strategy, and dose selection.
Strategic drug development
Innovative clinical drug development plans and study designs designed to enable informed and stepwise decision making for unique development programs.
Services
Advisory services to design customized clinical development plans and study designs aimed at efficient progression to clinical proof-of-concept and optimized probability of success.
Support in target and mode-of-action analysis, selection of translatable biomarkers and integration of preclinical data to improve clinical development success.
Services include PK/PD analyses, dose selection strategy, drug–drug interaction assessment, special population considerations and preparation of clinical pharmacology components of regulatory submissions.
Two-day basic pharmacokinetics course covering ADME, PK parameter concepts, parameter derivation, PK/PD use in development and ADME of therapeutic proteins.
Advisory services to design customized clinical development plans and study designs aimed at efficient progression to clinical proof-of-concept and optimized probability of success.
Support in target and mode-of-action analysis, selection of translatable biomarkers and integration of preclinical data to improve clinical development success.
Services include PK/PD analyses, dose selection strategy, drug–drug interaction assessment, special population considerations and preparation of clinical pharmacology components of regulatory submissions.
Two-day basic pharmacokinetics course covering ADME, PK parameter concepts, parameter derivation, PK/PD use in development and ADME of therapeutic proteins.
Expertise Areas
- Translational science and biomarker strategy
- Clinical pharmacology and dose finding
- Strategic drug development planning
- Early phase (first-in-human) study design
Key Technologies
- PK/PD modeling and simulation
- Physiology-based pharmacokinetic (PBPK) approaches
- In vitro and in vivo pharmacology
- In vitro–in vivo correlation (IVIVC)
News & Updates
Reported client repeat business rate greater than 90%.
Reported client repeat business rate greater than 90%.